PicoCELA Inc. (NASDAQ:PCLA) Sees Large Growth in Short Interest

PicoCELA Inc. (NASDAQ:PCLA) was the recipient of a significant increase in short interest during the month of May. As of May 29th, there was short interest totaling 126,693 shares, an increase of 1,375.2% from the May 14th total of 8,588 shares. Based on an average daily volume of 9,565,111 shares, the short-interest ratio is presently 0.0 days. Currently, 333.4% of the shares of the company are sold short.

Institutional Investors Weigh In On PicoCELA

An institutional investor recently bought a new position in PicoCELA stock. XTX Topco Ltd purchased a new stake in PicoCELA Inc. (NASDAQ:PCLA) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 44,648 shares of the company’s stock, valued at approximately $72,000. XTX Topco Ltd owned 0.16% of PicoCELA as of its most recent filing with the SEC.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of PicoCELA in a report on Wednesday, April 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, PicoCELA currently has an average rating of “Sell”.

PicoCELA Trading Up 3.4%

Shares of NASDAQ PCLA traded up $0.22 during trading on Thursday, hitting $6.62. The company had a trading volume of 4,674 shares, compared to its average volume of 825,916. PicoCELA has a fifty-two week low of $1.35 and a fifty-two week high of $112.20. The stock has a fifty day simple moving average of $3.68 and a two-hundred day simple moving average of $5.13. The company has a quick ratio of 1.57, a current ratio of 2.13 and a debt-to-equity ratio of 0.02.

PicoCELA Company Profile

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.